AKT1 and colorectal cancer: In a previous study by Diaz-Lagares et al., in vitro and in vivo assays showed that TP53TG1 has tumor-suppressor activity in colorectal cancer, increasing the sensitivity to DNA-damaging agents used in colorectal cancer (e.g., 5-fluorouracil + oxaliplatin) and small targeted molecules, such as PI3K and AKT inhibitors [14].